Vol. 4 No. 9 (2024)
Reimbursement Reviews

Bimekizumab (Bimzelx)

decorative image of the issue cover

Published September 19, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses bimekizumab (Bimzelx), 160 mg/mL, solution for subcutaneous injection.
  • Indication: The treatment of adult patients with active psoriatic arthritis (PsA). Bimzelx can be used alone or in combination with a conventional nonbiologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).